Cancer Therapy: Clinical

Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI

Matthew J. Wieduwilt1, Francisco Valles3, Samar Issa6, Caroline M. Behler1,2, James Hwang2, Michael McDermott2,4, Patrick Treseler2,5, Joan O’Brien1, Marc A. Shuman1,2, Soonmee Cha2,3, Lloyd E. Damon1,2, and James L. Rubenstein1,2

Abstract

Purpose: We evaluated a novel therapy for primary central nervous system lymphoma (PCNSL) with induction immunochemotherapy with high-dose methotrexate, temozolomide, and rituximab (MT-R) followed by intensive consolidation with infusional etoposide and high-dose cytarabine (EA). In addition, we evaluated the prognostic value of the minimum apparent diffusion coefficient (ADCmin) derived from diffusion-weighted MRI (DW-MRI) in patients treated with this regimen.

Experimental Design: Thirty-one patients (median age, 61 years; median Karnofsky performance score, 60) received induction with methotrexate every 14 days for 8 planned cycles. Rituximab was administered the first 6 cycles and temozolomide administered on odd-numbered cycles. Patients with responsive or stable central nervous system (CNS) disease received EA consolidation. Pretreatment DW-MRI was used to calculate the ADCmin of contrast-enhancing lesions.

Results: The complete response rate for MT-R induction was 52%. At a median follow-up of 79 months, the 2-year progression-free and overall survival were 45% and 58%, respectively. For patients receiving EA consolidation, the 2-year progression-free and overall survival were 78% and 93%, respectively. EA consolidation was also effective in an additional 3 patients who presented with synchronous CNS and systemic lymphoma. Tumor ADCmin less than 384 $\times$ $10^{-6}$ mm$^2$/s was significantly associated with shorter progression-free and overall survival.

Conclusions: MT-R induction was effective and well tolerated. MT-R followed by EA consolidation yielded progression-free and overall survival outcomes comparable to regimens with chemotherapy followed by whole-brain radiotherapy consolidation but without evidence of neurotoxicity. Tumor ADCmin derived from DW-MRI provided better prognostic information for PCNSL patients treated with the MTR-EA regimen than established clinical risk scores.

Clin Cancer Res; 18(4); 1–10. ©2012 AACR.

Introduction

Novel therapeutic approaches that improve efficacy but avoid the deleterious neurocognitive effects of treatment, in particular those of standard dose whole brain radiotherapy (WBRT), are needed in primary central nervous system lymphoma (PCNSL). The problem of radiation-induced delayed neurotoxicity is particularly significant for the approximate one-half of PCNSL patients older than 60 years (1). Although a preliminary report provided evidence that reduced dose whole brain irradiation (23.4 Gy) in conjunction with chemotherapy caused less neurotoxicity than standard dose WBRT (45 Gy; ref. 2), additional follow-up and validation of these results are needed and there remains a general concern that radiation-induced encephalopathy is a particularly undesirable and irreversible, treatment-associated morbidity.

High-dose methotrexate now represents the cornerstone of therapy in PCNSL (3). In contrast to WBRT, treatment...
Translational Relevance

Here, we report on the long-term follow-up of the first cohort of newly diagnosed primary central nervous system lymphoma (PCNSL) patients treated with a novel induction and consolidation regimen, without brain radiotherapy: methotrexate–temozolomide–rituximab (MT-R) followed by 96-hour infusional etoposide plus high-dose cytarabine (EA). This study, which includes the outcomes of a pilot phase I trial that evaluated this regimen, is the first to evaluate a dose-intensive consolidation chemotherapy regimen that includes high-dose etoposide but involves neither autologous stem cell transplantation nor whole brain radiotherapy in newly diagnosed PCNSL patients. In addition, we evaluated the prognostic utility of diffusion-weighted MRI (DW-MRI) in a uniformly treated cohort of PCNSL patients treated with MTR-EA. Our results show that MTR-EA therapy resulted in progression-free and overall survival similar to that achieved with high-dose methotrexate-based regimens using consolidation with standard or reduced-dose brain irradiation. In addition, our results, with follow-up of 79 months, suggest that DW-MRI is a potentially important, noninvasive tool to assess prognosis at diagnosis and that this analysis should be prospectively evaluated in future studies using high-dose methotrexate-based induction, in particular trials which evaluate the MT-R regimen. Furthermore, our results suggest that noninvasive DW-MRI characteristics could be used in risk stratification in future clinical trials that evaluate novel biological therapies for patients with PCNSL who are at risk of early tumor progression.

With high-dose methotrexate alone does not seem to frequently cause clinically severe neurocognitive impairment (4). However, high-dose methotrexate monotherapy is rarely curative with at least 70% of patients exhibiting disease progression within 2 years (5, 6).

Our goal has been to develop a dose-intensive chemotherapeutic regimen that is tolerated by the majority of PCNSL patients, particularly during the first weeks after diagnosis when neurologic function and performance status are most compromised. For the past 10 years at the University of California, San Francisco (UCSF), newly diagnosed PCNSL patients have been treated with a novel, 2-step immunotherapy program involving 4 months of induction therapy using intravenous high-dose methotrexate with oral temozolomide and intravenous rituximab (MT-R) followed by high-dose consolidation chemotherapy, without WBRT.

In the regimen, high-dose methotrexate with leucovorin rescue is given every 14 days for a planned 8 treatments. Standard dose intravenous rituximab is administered during the first 2 months of therapy, a window in which the blood-brain barrier is most often significantly compromised (7), and we hypothesized that it would permit the delivery of rituximab to the tumor. Temozolomide has high relative lipophilicity with reliable central nervous system (CNS) penetration and a superior toxicity and health-related quality of life profile in brain tumor patients compared with procarbazine (8, 9). Temozolomide is active at relapse in PCNSL, both as monotherapy and in combination with rituximab (10–12).

To attempt to potentiate long-term, progression-free survival (PFS) after MT-R, PCNSL patients with at least stable disease (SD) received intensive consolidation chemotherapy with non–cross-resistant agents: 96-hour infusional etoposide plus high-dose, twice-daily cytarabine (EA; refs. 13–15). A similar combination of etoposide plus high-dose cytarabine was shown by Soussain and colleagues to be active as salvage therapy in recurrent/refractory primary and secondary CNS lymphoma, with 12 of 14 patients exhibiting responses, 8 of which were complete responses (CR; ref. 16). Moreover 96-hour infusional etoposide has been incorporated within the EPOCH regimen, which is highly active in large cell lymphoma (17, 18), the most common histology to affect the CNS. A variety of reports have shown the activity of etoposide in treating brain tumors, including lymphoid leukemia involving the CNS (19). The use of etoposide has also been associated with a significant reduction in the risk of secondary CNS lymphoma, when given in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with aggressive lymphoma (20). The importance of high-dose cytarabine in PCNSL was also recently underscored in a randomized phase II study (21).

Diffusion-weighted imaging (DWI) is a noninvasive MRI technique that produces in vivo images of brain based on differential rate of water diffusion or Brownian motion within the extracellular space. DWI is an essential tool to diagnose acute infarct in the brain due to its ability to detect early changes in altered water diffusion due to cellular damage. DWI has also been widely used in neuro-oncology to assess tumor biology. Specifically, the apparent diffusion coefficient (ADC) values derived from DWI have been shown to correlate with glioma grade (22, 23), tumor cellularity (24), and treatment response (25–31). A recent study also suggests that ADC values may be helpful in predicting clinical outcome in immunocompetent patients with primary CNS lymphoma (32).

In this analysis, we describe the toxicity and long-term outcome of the first PCNSL patients to be treated with combination MT-R followed by EA at UCSF Medical Center, between 2001 and 2006. This study represents the first analysis of the survival of newly diagnosed PCNSL patients to receive a dose-intensive consolidation chemotherapy regimen that involves neither autologous stem cell transplantation nor WBRT. This study also represents the first analysis of the role of etoposide as a component of consolidation in newly diagnosed patients with CNS lymphoma. Finally, we evaluated diffusion-weighted MRI (DW-MRI) as a noninvasive tool to determine tumor minimal ADC (ADC_{min}) at diagnosis as a biomarker predictive of prognosis for PCNSL patients who receive MT-R induction therapy.
Patients and Methods

Patient characteristics

The primary study population included 31 immunocompetent patients with newly diagnosed, histologically or cytologically proven PCNSL treated at the UCSF Comprehensive Cancer Center beginning in 2001 and ending in 2006. There was no restriction with respect to age or performance status. Ten subjects were enrolled on UCSF protocol 03301, a prospective phase I trial with stopping rules for 2 safety endpoints: hematologic toxicity (prolonged leucopenia during induction MT-R) and neurotoxicity (grade 3 or 4 neurotoxicity during EA consolidation). The outcome of an additional 3 immunocompetent patients who presented with brain parenchymal involvement of CNS lymphoma of aggressive histology with systemic involvement at pretreatment staging and who were treated with EA consolidation, is presented as well. The retrospective analysis of treatment, toxicities, and outcomes for all patients was approved by the UCSF Institutional Review Board (I9414-23160). Pretreatment diagnosis and staging, including complete ophthalmologic examinations, as well as restaging after initiation of treatment, was carried out in accordance with guidelines established by the International Primary CNS Lymphoma Collaborative Group (IPCG; ref. 33).

Mandatory baseline laboratory values required absolute neutrophil count (ANC) more than 1,500/mcl, AST and ALT 2 times or lesser than the upper limit of normal (ULN), total bilirubin 2 times or lesser than the ULN, and measured creatinine clearance of 50 mL/min or more. Prior to the first dose of methotrexate, creatinine clearance was determined by 24-hour urine collection. In subsequent treatment cycles, the Cockcroft-Gault equation was used to estimate creatinine clearance.

Remission induction immunochemotherapy

Treatment cycles were 14 days in length (Table 1). Sulfonamide drugs, trimethoprim, salicylates, nonsteroidal anti-inflammatory drugs, penicillins, vitamin C, ciprofloxacin, and proton pump inhibitors were held at least 48 hours prior to methotrexate administration. Hydration and urine alkalinization was achieved by administration of NaHCO3 (100–150 mEq/L) at 150 mL/h intravenously until urine output of 100 mL/h or more and urine pH more than 7 for 4 hours prior to methotrexate and continued until completion of leucovorin rescue. Intravenous methotrexate (8 g/m2) was given over 4 hours on day 1 of each 14-day cycle followed 24 hours later by leucovorin (100 mg/m2) i.v. every 6 h i.v. until serum methotrexate <0.05 μmol/L. Leucovorin (100 mg/m2) i.v. was administered for at least 24 h to achieve a serum methotrexate level less than 0.05 μmol/L. Methotrexate dose was reduced for decreased creatinine clearance, as described (5). Intravenous rituximab (375 mg/m2) was given on day 3 of each cycle for a total of 6 doses.

Table 1. Treatment schema

| Remission induction therapy, MT-R (14-day cycle, 8 cycles) | Day 1 | Methotrexate (8 g/m2) i.v. over 4 h |
| Day 2 | Leucovorin (100 mg/m2) every 6 h i.v. until serum methotrexate <0.05 μmol/L |
| Day 3 | Rituximab (375 mg/m2) i.v. cycle 1 through 6a |
| Day 7–11 | Temozolomide (150 mg/m2) oral daily (odd cycles only) |

Consolidation therapy, EA (1 cycle)

| Day 1–4 | Etoposide (5 mg/kg) continuous i.v. over 12 h every 12 h × 8 doses |
| Day 1–4 | Cytarabine (2 gm/m2) i.v. over 2 h every 12 h × 8 doses |

8aRituximab omitted for T-cell lymphoma.

Diphenhydramine (25–50 mg) and acetaminophen (650 mg) were administered prior to rituximab. The patient with T-cell lymphoma did not receive rituximab. Oral temozolomide (150 mg/m2) was given daily on days 7 to 11 during the odd numbered cycles for a total of 4 cycles. No intrathecal therapy was administered. Patients were evaluated for response after 6 cycles of MT-R. If a CR was obtained, the patient was treated with 2 additional cycles of methotrexate and temozolomide before high-dose consolidation chemotherapy. If a partial response (PR) was observed, the patient was treated with between 3 and 5 additional cycles of induction methotrexate and temozolomide before consolidation.

Patients with synchronous brain parenchymal and systemic lymphoma received both high-dose methotrexate at 8 grams/m2 with leucovorin rescue every 2 weeks, for a total of 8 cycles and standard dose R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) every 3 weeks for 6 cycles. When R-CHOP and high-dose methotrexate were given during the same week, high-dose methotrexate was administered on day 1 and R-CHOP was administered starting on day 3.

Consolidation chemotherapy

Patients with PCNSL as well as the 3 CNS lymphoma patients with synchronous brain parenchymal and systemic lymphoma were offered inpatient high-dose therapy with etoposide and cytarabine (EA) if they achieved stable disease or better after 8 cycles of methotrexate-based induction. Three patients elected to receive up to 3 additional cycles of methotrexate before proceeding to intensive consolidation. The median number of methotrexate cycles for all patients who received EA consolidation was 8. Etoposide (5 mg/kg) was given by continuous i.v. infusion every 12 hours for 8 doses (40 mg/kg total dose) with cytarabine (2 grams/m2) i.v. over 2 hours every 12 hours for 8 doses (total dose: 16 gm/m2). Corticosteroid eye drops, 2 drops per eye, were
given 4 times per day, days 1 to 6 to prevent cytarabine keratoconjunctivitis. Patients showered twice daily during cytarabine treatment days. G-CSF (5 mcg/kg/d) was given subcutaneously starting day 14 of therapy and continued until ANC 500/mcl or more for 2 days or 1,500/mcl or more for 1 day. Bacterial prophylaxis with fluoroquinolone (moxifloxacin or levofloxacin) antibiotics was initiated atANC less than 500/mcl and continued until ANC of 500/mcl or more. Fungal prophylaxis consisted of fluconazole or voriconazole starting day 6 of therapy and continuing until ANC of 500/mcl or more. Herpes simplex virus and Varicella zoster virus prophylaxis consisted of acyclovir or valacyclovir. Pneumocystis pneumonia prophylaxis was provided with trimethoprim/sulfamethoxazole or dapsone. Packed red blood cell or platelet transfusions were given for Hct less than 26% or platelets less than 10,000/mcl, respectively. All blood products were leukoreduced in line during transfusion.

**Evaluation of toxicity and response**
Toxicity was graded by the National Cancer Institute Common Toxicity Criteria for Adverse Events (version 4.0). Tumor responses were evaluated by gadolinium-enhanced MRI of the brain after every second or third cycle, and in all cases after cycle 8 of HD-MTX and after EA consolidation therapy (33). For patients with initial positive CSF cytology, repeat lumbar punctures were carried out to assess response. Response assessment was per IPCG Guidelines (33).

**MR imaging and determination of ADCmin**
We previously reported that the ADCmin of contrast-enhancing lesions correlated with outcome in PCNSL patients treated with high-dose methotrexate-based therapies (32). We therefore applied this method to those PCNSL patients treated at our institution who were treated with combination MT-R induction between 2001 and 2006 to assess the relationship between pretreatment intratumoral water diffusion and response, PFS, and overall survival (OS) in patients treated with this regimen. Eight of these patients were included in our previous report. Prior to therapy, patients underwent brain MRI without and with intravenous contrast.

All patients were imaged with a 1.5 Tesla clinical MR scanner (Signa Horizon, GE Healthcare). MRI examinations included conventional contrast-enhanced T1-weighted imaging and DWI sequences obtained according to a standardized protocol: 3-plane localizer (TR/TE, 8.5/1.6 ms), sagittal T1-weighted spin-echo (TR/TE, 600/17 ms), axial 3D T2-weighted fast spin-echo (TR/TE, 3000/102 ms), axial fluid-attenuated inversion recovery (FLAIR; TR/TE/TI, 10,000/148/2200 ms), axial DWI echo-planar imaging (TR/TE, 10,000/99 ms; section thickness/intersection gap, 5/0 mm; matrix size, 256 × 256 × 24; FOV, 24 cm; 3-directions, b-value, 0 and 1000 s/mm²) acquired in the transverse plane throughout the infratentorial and supratentorial brain, and contrast-enhanced three-dimensional spoiled gradient-recalled acquisition in the steady state (SPGR) T1-weighted imaging (TR/TE, 34/8 ms; section thickness/intersection gap, 1.5/0 mm).

Gadopentetate dimeglumine (Magnevist, Bayer Healthcare) was the intravenous contrast agent for the MRI study and the dose used was 0.1 mmol/kg body weight.

From the raw DWI data set, the ADC map was reconstructed based on pixel-by-pixel display of diffusion coefficient in 3 different directions and fitting diffusion signal intensities to the Stejskal-Tanner equation, S(b) = S(0) exp (-b ADC), using a least-squares approach. The ADC map was then coregistered with the axial contrast-enhanced T1-weighted images at regions of interest (ROI). For each patient, the ROIs were drawn on the postcontrast T1-weighted images outlining all contrast-enhancing tumor by one investigator. All ROIs were checked and approved by the attending neuroradiologist involved in the study (S.C.). In 10 patients, 2 different investigators drew ROIs independently and were verified by the neuroradiologist to be repeatable and reproducible. The ADCmin was determined within the ROIs of the contrast-enhancing tumor region as described (32). The neuroradiologist determining the ADCmin was blinded to patient outcomes at the time of ADCmin determination. All ADC values are reported as 100 × 10^-6 mm²/s.

**Data analysis**
PFS and OS were determined by Kaplan–Meier analysis. Survival curves were compared with the log-rank test. Response rates between Memorial Sloan Kettering Cancer Center (MSKCC) risk groups, International Extranodal Lymphoma Study Group (IELSG) risk groups, and ADCmin category were compared with the Fisher exact test.

**Results**

**Patient characteristics**
Baseline clinical characteristics of the 31 PCNSL patients are summarized in Table 2. Median age was 61 years (range 40–84) with median Karnofsky performance score of 60 (range 50–100). Diffuse large B-cell lymphoma accounted for 25 of the 31 cases (81%) with lymphoblastic lymphoma (n = 2, 6.5%), Burkitt-like lymphoma (n = 2, 6.5%), aggressive B-cell lymphoma, unspecified (n = 1, 3%), and T-cell lymphoma (n = 1, 3%) accounting for the remainder of cases. Twenty-one patients (68%) had deep brain lesions, and 2 patients (6.5%) had isolated leptomeningeal disease. CSF cytology was positive for lymphoma in 6 of 26 cases evaluated (23%). Ocular involvement was evident in 1 patient (3%) at diagnosis.

The 3 patients with synchronous brain parenchymal CNS and systemic lymphoma ranged in age from 45 to 55 years and all had large B-cell lymphoma. Biopsy proven extra-CNS sites of disease for these patients were bone marrow, adrenal gland, and occipital bone with associated musculature.

**Toxicity**
Toxicity of methotrexate, temozolomide, and rituximab (MT-R) induction. MT-R was well tolerated. Grade 3 or
4 adverse events occurring in more than 1 patient included reversible transaminitis in 7 patients and neutropenia in 3 patients with no episodes of febrile neutropenia. No patient developed grade 2 or greater CNS toxicity. One treatment-related death occurred in an 81-year-old patient from concurrent *Pneumocystis jiroveci* and Cytomegalovirus pneumonia in the setting of tumor progression. Among the 3 patients receiving high-dose methotrexate in combination with R-CHOP for systemic lymphoma with CNS involvement, grade 3 to 4 adverse events included neutropenia (100%), anemia (33%), thrombocytopenia (33%), transaminitis (33%), and neutropenic fever (33%).

**Toxicity of high-dose etoposide and cytarabine (EA) consolidation.** Seventeen patients received EA consolidation chemotherapy. The median length of hospital stay was 20 days (range 19–28). As expected, all patients developed grade 4 neutropenia and thrombocytopenia. Patients had a median of 10 days of severe neutropenia (ANC <500/mcL, range 8–12 days) with 14 patients experiencing fever (temperature ≥38.3°C). Grade 4 febrile neutropenia occurred in 1 patient. Infectious organisms identified in 5 patients were *Clostridium difficile* (stool, 2 cases), *Staphylococcus epidermidis* (blood, 2 cases), *Enterococcus faecalis* (blood, 1 case), *Enterococcus faecium* (blood, 1 case), *Citrobacter freundii* (blood, 1 case), *Escherichia coli* (blood, 1 case; urine, 1 case), and *Klebsiella pneumoniae* (urine, 1 case). Patients spent a median of 2 days with platelets less than 20,000/mcL (range 1–8 days) and a median of 9 days of platelets less than 50,000/mcL (range 7–20). The median number of platelet transfusions was 2 (range 1–5), and the median number of packed RBC transfusions was 2 (range 0–4). Common grade 1 to 3 nonhematologic toxicities in more than 30% of patients included nausea (82%), diarrhea (82%), rash (65%), vomiting (41%), reversible transaminitis (41%), hyperbilirubinemia (35%), and mucositis (35%). The only grade 4 nonhematologic adverse event was hyponatremia associated with confusion in 1 patient (nadir Na 118 mmol/L). One patient required intensive care monitoring for 2 days for febrile neutropenia with transient hypotension. There was no grade 3 or 4 neurotoxicity, and there were no treatment-related deaths during intensive consolidation (Table 3).

**Response to induction immunochemotherapy**

All 31 patients received at least 1 full cycle of MT-R. Eighteen patients responded in total (ORR = 58%) with...
16 patients (52%) achieving a CR, 15 within 8 cycles of methotrexate, and 1 after 9 cycles (Tables 4 and 5). One of the 2 partial responders had concomitant primary intraocular and brain parenchymal lymphoma and achieved complete resolution of all intracranial lesions but only partial resolution of intraocular lymphoma after induction MT-R. One patient maintained stable disease throughout MT-R and went on to EA consolidation. Twelve patients exhibited radiographic progression before completion of planned induction MT-R. Each of the 3 patients with synchronous brain parenchymal CNS and systemic lymphoma treated with high-dose methotrexate plus R-CHOP achieved a CR within all sites of disease after 4 cycles of methotrexate and R-CHOP.

**High-dose etoposide and cytarabine consolidation**

A total of 14 PCNSL patients received EA consolidation, 12 of whom were in CR after MT-R induction (1 was in PR and 1 with stable disease). The one patient with stable disease to MT-R had a PR with EA treatment with concomitant sustained neurologic improvement and is alive without progression 80 months after the start of therapy. One patient had progressive intracranial lymphoma after EA consolidation of an initial PR to induction MT-R and ultimately required external beam radiotherapy after the EA consolidation to eliminate disease in the intracranial compartment. Since completion of EA and ocular radiotherapy, the patient has been disease free for 54 months. Two patients died of progressive disease (PD) after receiving EA consolidation.

Of the 4 PCNSL patients in CR after induction who decided not to pursue EA consolidation, one died from progressive CNS lymphoma 6 years after completion of MT-R and 3 are alive at last follow-up, without evidence of disease. One patient in PR after 8 cycles of methotrexate-based induction pursued autologous stem cell transplant but succumbed to disease progression 3 months later.

### Table 4. Individual patient outcomes

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (y)</th>
<th>Histology</th>
<th>Response to MTR</th>
<th>EA consolidation</th>
<th>PFS (mo)</th>
<th>OS (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>107</td>
<td>107</td>
</tr>
<tr>
<td>2</td>
<td>40</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>123</td>
<td>123</td>
</tr>
<tr>
<td>3</td>
<td>54</td>
<td>Lymphoblastic lymphoma</td>
<td>PD</td>
<td>No</td>
<td>1.1</td>
<td>9.8</td>
</tr>
<tr>
<td>4</td>
<td>47</td>
<td>DLBCL</td>
<td>PR</td>
<td>No</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>5</td>
<td>71</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>52</td>
<td>DLBCL</td>
<td>CR</td>
<td>No</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>7</td>
<td>43</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>8.7</td>
<td>11</td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>DLBCL</td>
<td>CR</td>
<td>No</td>
<td>104</td>
<td>104</td>
</tr>
<tr>
<td>9</td>
<td>45</td>
<td>Burkitt-like lymphoma</td>
<td>PD</td>
<td>No</td>
<td>2</td>
<td>22</td>
</tr>
<tr>
<td>10</td>
<td>62</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>1</td>
<td>17</td>
</tr>
<tr>
<td>11</td>
<td>68</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>8</td>
<td>8.5</td>
</tr>
<tr>
<td>12</td>
<td>79</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>4</td>
<td>6.5</td>
</tr>
<tr>
<td>13</td>
<td>65</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>95</td>
<td>95</td>
</tr>
<tr>
<td>14</td>
<td>59</td>
<td>Aggressive B-cell NHL</td>
<td>CR</td>
<td>Yes</td>
<td>24</td>
<td>66</td>
</tr>
<tr>
<td>15</td>
<td>61</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>91</td>
<td>91</td>
</tr>
<tr>
<td>16</td>
<td>50</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>1.2</td>
<td>6.4</td>
</tr>
<tr>
<td>17</td>
<td>81</td>
<td>Lymphoblastic lymphoma</td>
<td>CR</td>
<td>No</td>
<td>77</td>
<td>83</td>
</tr>
<tr>
<td>18</td>
<td>53</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>19</td>
<td>79</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>20</td>
<td>67</td>
<td>DLBCL</td>
<td>CR</td>
<td>No</td>
<td>51</td>
<td>51</td>
</tr>
<tr>
<td>21</td>
<td>84</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>22</td>
<td>67</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>23</td>
<td>49</td>
<td>DLBCL</td>
<td>PD</td>
<td>No</td>
<td>3</td>
<td>42.3</td>
</tr>
<tr>
<td>24</td>
<td>62</td>
<td>DLBCL</td>
<td>SD</td>
<td>Yes</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>25</td>
<td>63</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>79</td>
<td>79</td>
</tr>
<tr>
<td>26</td>
<td>66</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>54</td>
<td>54</td>
</tr>
<tr>
<td>27</td>
<td>52</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>71</td>
<td>71</td>
</tr>
<tr>
<td>28</td>
<td>54</td>
<td>Burkitt-like lymphoma</td>
<td>CR</td>
<td>Yes</td>
<td>62</td>
<td>62</td>
</tr>
<tr>
<td>29</td>
<td>54</td>
<td>DLBCL</td>
<td>PR</td>
<td>Yes</td>
<td>6</td>
<td>54</td>
</tr>
<tr>
<td>30</td>
<td>64</td>
<td>T-cell NHL</td>
<td>PD</td>
<td>No</td>
<td>3.8</td>
<td>5.7</td>
</tr>
<tr>
<td>31</td>
<td>54</td>
<td>DLBCL</td>
<td>CR</td>
<td>Yes</td>
<td>56</td>
<td>56</td>
</tr>
</tbody>
</table>

Abbreviations: DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin lymphoma; SD, stable disease; PD, progressive disease.
Table 5. Response rates and survival after MT-R, MT-R followed by EA, and by pretreatment ADC_{min} values

<table>
<thead>
<tr>
<th></th>
<th>CR</th>
<th>PR</th>
<th>Overall response</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
</tr>
<tr>
<td>MT-R</td>
<td>31</td>
<td>16</td>
<td>52</td>
</tr>
<tr>
<td>MT-R → EA</td>
<td>14</td>
<td>10</td>
<td>67</td>
</tr>
<tr>
<td>ADC_{min} (×10^{-6} mm²/s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;384</td>
<td>15</td>
<td>10</td>
<td>67</td>
</tr>
<tr>
<td>&lt;384</td>
<td>8</td>
<td>2</td>
<td>25</td>
</tr>
</tbody>
</table>

Abbreviations: MT-R, all patients receiving rituximab, methotrexate and temozolomide; MT-R → EA, patients receiving MT-R followed by high-dose etoposide and cytarabine consolidation; NR, not reached.

With a median follow-up of 79 months (range 48–123 months) for all PCNSL patients who received MT-R induction, with or without EA consolidation, the 2-year PFS was 45% (95% CI: 30–58; Fig. 1A). For the subgroup of MT-R patients who also received consolidation with high-dose EA, the 2-year PFS was 79% (95% CI: 43–90; Fig. 1B). None of the 3 patients with synchronous brain parenchymal CNS and systemic lymphoma treated with EA consolidation have relapsed with a median follow-up of 66 months (range, 44–79 months; Fig. 1C).

Prognostic assessment using DW-MRI and by clinical parameters

We were able to determine ADC_{min} by DW-MRI of contrast-enhancing lesions at diagnosis for 23 of the 31 patients (74%) in this cohort. Using ADC_{min} less than 384 × 10^{-6} mm²/s as a cutoff, as defined in our earlier report (32), we observed that patients whose tumors exhibited severely reduced water diffusion (ADC_{min} < 384 × 10^{-6} mm²/s) had significantly worse outcome compared with patients whose tumors showed an ADC_{min} of more than 384 × 10^{-6} mm²/s (Table 5; Fig. 2). Patients in the low ADC_{min} group who received MT-R had a median PFS of only 2 months, whereas median PFS was not reached for patients in the high ADC_{min} group (P = 0.007). OS was also shorter in patients with CNS lymphomas that displayed markedly reduced water diffusion when treated with MT-R (P = 0.003).

We also evaluated clinical prognostic variables proposed in the IELSG scoring system for 24 evaluable patients and by the MSKCC model for all PCNSL patients in this study (Supplementary Table S1; 35, 36). The MSKCC prognostic classification system did not identify significant survival differences in this study. However, IELSG prognostic groups 2 to 3 patients exhibited superior PFS and OS compared with IELSG groups 4 to 5 (2-year PFS 70% vs. 30%, P = 0.04; 2-year OS 70% vs. 40%, P = 0.05).

Discussion

In this study, we analyze the toxicity, responses, and long-term survival of newly diagnosed PCNSL patients treated with a novel 2-step intensive immunochemotherapy strategy not involving autologous stem cell transplantation or WBRT. The rate of CR to MT-R was 52%, comparable with but not substantially higher than the 30% to 52% rate of CR to high-dose methotrexate alone in PCNSL described in earlier studies (5, 6). Although only 1 PCNSL patient had an improved response with EA consolidation (stable disease to CR), our patients as a whole showed excellent PFS and OS and did so without the cognitive morbidity typically associated with WBRT. However, given that the majority of patients who achieved a CR with MT-R subsequently received a novel intensive consolidation, it is impossible to define the potential contribution of rituximab and temozolomide to long-term PFS and OS within this regimen. Nevertheless, our results with the MT-R regimen show that it is possible to combine an alkylating agent with high-dose methotrexate without additive toxicity. Moreover, the 2-year PFS of PCNSL patients treated with MT-R followed by intensive consolidation with EA in this series is markedly longer than the rates of 2-year PFS described in previous series using intravenous chemotherapy alone without brain irradiation (5, 37–39).

Despite a relatively high CR rate, one-third of our patients had clinical and radiographic progression within the first 4 cycles of MT-R therapy, and none of these were long-term survivors. This illustrates the significant clinical problem of primary drug resistance in PCNSL. High rates of primary induction failure are reported in virtually all clinical series in PCNSL (2, 5, 21, 40), yet the issue of early refractory disease has not been emphasized. We suggest that future treatment programs for PCNSL evaluate risk-adapted strategies that selectively implement novel approaches for patients at high risk of early tumor progression, such as those with low ADC_{min} values at initial diagnosis.

On the basis of these data, DW-MRI of contrast-enhancing tumor may be a potentially valuable method for risk stratification in PCNSL patients at diagnosis. Of note, one of the 2 patients in the low ADC group who did well with MTR-EA therapy had an intratumoral ADC_{min} of 365 × 10^{-6} mm²/s, the highest value in the low ADC_{min} cohort and near the cutoff point of 384 × 10^{-6} mm²/s, suggesting that...
further studies are needed to refine ADC as a biomarker of high-risk subpopulations of PCNSL patients. Nevertheless, when applied to the MTR-EA regimen in PCNSL, diffusion-weighted imaging provided better prognostic information than established indices based on clinical variables that were developed in the setting of WBRT (35, 36). A limitation of this study is that the IELSG prognostic system could only be applied to 24 of 31 patients, limiting its power, and thus additional studies are required to prospectively validate these preliminary conclusions and to potentially refine the diffusion methodology and cut point ADC\textsubscript{min} value.

On long-term follow-up, our findings suggest that combination high-dose infusional etoposide plus cytarabine (EA) is highly effective as consolidation after MT-R induction in newly diagnosed patients with PCNSL and after R-CHOP plus high-dose methotrexate treatment for patients with stage IV diffuse large B-cell lymphoma (DLBCL) with CNS involvement. Of the 14 PCNSL patients who received MT-R followed by EA consolidation, 12 remain in remission with a median follow-up of 79 months, and there has not been disease progression outside of the 2-year window postinduction. Similarly, none of the 3 patients with synchronous brain parenchymal CNS and systemic lymphoma who were treated with EA have progressed, with a median follow-up of 66 months; results which are markedly superior to nonstandardized approaches used in the treatment of synchronous CNS and systemic lymphoma described in a recent series in which the median PFS was only 7 months. (42)

In addition, we have detected no significant acute or delayed neurologic toxicity related to this treatment in long-term evaluation as 15 of the 17 patients treated with EA have regained their pre-CNS lymphoma performance status. Five have maintained their professions at the same level as before MTR-EA and the median minimental status examination score evaluated in 12 out of 18 surviving CNS lymphoma patients was 29 (range 25–30) a median of 5 years after treatment. However, it is likely that more detailed neurocognitive testing would identify subtle but persistent disease-associated and potentially treatment-associated deficits. Based upon our data, we propose that EA consolidation be considered as an alternative to WBRT in patients with either primary or secondary CNS lymphoma. These promising results are the basis for a multicenter study through CALGB that is evaluating the response rate, toxicity, and long-term efficacy of the MTR-EA regimen in patients with PCNSL (43). The regimen is also now in development for evaluation in a successor, intergroup randomized phase II study.

In our series, EA was also active as a first-line salvage regimen in patients who progressed on MT-R, in that all 4 patients with primary refractory disease who received EA exhibited CRs. However, each of these patients ultimately experienced tumor progression before planned myeloablative therapy and autologous stem cell rescue. Five patients with primary refractory disease received immediate salvage WBRT that was associated with a median survival of only 10

Figure 1. Kaplan–Meier survival curves. A, PFS and OS of the entire cohort of PCNSL patients treated with MT-R ± EA (\(n=31\)). B, survival of the PCNSL patients (\(n=14\)) who completed both MTR and EA consolidation. C, survival of all CNS lymphoma patients treated with EA consolidation (\(n=17\)) including the PCNSL patients (\(n=14\)) treated with MTR-EA and the secondary CNS lymphoma patients (\(n=3\)) treated with MT-R-CHOP-EA.
months (range 6–42 months). These results highlight a need for the introduction of new biological agents to augment the efficacy of currently available chemotherapeutic and immunotherapeutic approaches, particularly during the induction phase for PCNSL.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


Grant Support

This work was supported by the Leukemia & Lymphoma Society and by NIH R01CA139-83-01A1 (J.L. Rubenstein).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 15, 2011; revised November 18, 2011; accepted December 22, 2011; published OnlineFirst January 6, 2012.


Clinical Cancer Research

Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI

Matthew J. Wieduwilt, Francisco Valles, Samar Issa, et al.

Clin Cancer Res  Published OnlineFirst January 6, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-0625

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/01/06/1078-0432.CCR-11-0625.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.